Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Hyperinflammation and cytokine storm has been noted as a poor prognostic factor in patients with severe pneumonia related to coronavirus disease 2019 (COVID-19). In COVID-19, pathogenic myeloid cell overactivation is found to be a vital mediator of damage to tissues, hypercoagulability, and the cytokine storm. These cytokines unselectively infiltrate various tissues, such as the lungs and heart, and nervous system. This cytokine storm can hence cause multi-organ dysfunction and life-threatening complications. Mavrilimumab is a monoclonal antibody (mAb) that may be helpful in some cases with COVID-19. During an inflammation, Granulocyte-macrophage colony-stimulating factor (GM-CSF) release is crucial to driving both innate and adaptive immune responses. The GM-CSF immune response is triggered when an antigen attaches to the host cell and induces the signaling pathway. Mavrilimumab antagonizes the action of GM-CSF and decreases the hyperinflammation associated with pneumonia in COVID-19, therefore strengthening the rationale that mavrilimumab when added to the standard protocol of treatment could improve the clinical outcomes in COVID-19 patients, specifically those patients with pneumonia. With this review paper, we aim to demonstrate the inhibitory effect of mavrilimumab on cytokine storms in patients with COVID-19 by reviewing published clinical trials and emphasize the importance of extensive future trials.
Abstract
Hyperinflammation and cytokine storm has been noted as a poor prognostic factor in patients with severe pneumonia related to coronavirus disease 2019 (COVID-19). In COVID-19, pathogenic myeloid cell overactivation is found to be a vital mediator of damage to tissues, hypercoagulability, and the cytokine storm. These cytokines unselectively infiltrate various tissues, such as the lungs and heart, and nervous system. This cytokine storm can hence cause multi-organ dysfunction and life-threatening complications. Mavrilimumab is a monoclonal antibody (mAb) that may be helpful in some cases with COVID-19. During an inflammation, Granulocyte-macrophage colony-stimulating factor (GM-CSF) release is crucial to driving both innate and adaptive immune responses. The GM-CSF immune response is triggered when an antigen attaches to the host cell and induces the signaling pathway. Mavrilimumab antagonizes the action of GM-CSF and decreases the hyperinflammation associated with pneumonia in COVID-19, therefore strengthening the rationale that mavrilimumab when added to the standard protocol of treatment could improve the clinical outcomes in COVID-19 patients, specifically those patients with pneumonia. With this review paper, we aim to demonstrate the inhibitory effect of mavrilimumab on cytokine storms in patients with COVID-19 by reviewing published clinical trials and emphasize the importance of extensive future trials.
참고문헌 (33)
- Singh Tomar PP, "SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine", Biochem Biophys Res Commun, 530, pp.10~14 (2020)
- Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280 (2020)
- Bonaventura A, "Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies", Front Immunol, 1, pp.1625~ (2020)
- Trapnell BC, "Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages", Curr Opin Immunol, 21, pp.514~521 (2009)
- Bhattacharya P, "Dual Role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy", J Interferon Cytokine Res, 35, pp.585~599 (2015)
- . Burmester GR, "Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, doubleblind, placebo-controlled, phase I, first-in-human study", Ann Rheum Dis, 70, pp.1542~1549 (2011)
- McClure BJ, "Molecular assembly of the ternary granulocyte-macrophage colony-stimulating factor receptor complex", Blood, 101, pp.1308~1315 (2003)
- Broughton SE, "The GM-CSF", IL-3, Immunol Rev, pp.2012, 250[DOI]
- Hamilton JA, "GM-CSF as a target in inflammatory", autoimmune disease: current evidence and future therapeutic potential, 2015, pp.11, 457~465
- Hamilton JA, "GM-CSF in inflammation and autoimmunity", Trends Immunol, 23, pp.403~408 (2002)
- Cardone M, "Lessons learned to date on COVID-19 hyperinflammatory syndrome: considerations for interventions to mitigate SARS-CoV-2 viral infection and detrimental hyperinflammation", Front Immunol, 11, pp.1131~ (2020)
- Nicholls JM, "Lung pathology of fatal severe acute respiratory syndrome", Lancet, 361, pp.1773~1778 (2003)
- Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019pneumonia in Wuhan, China", JAMA Intern Med, 180, pp.934~943 (2020)
- Griffin JD, "The biology of GM-CSF:regulation of production and interaction with its receptor", Int J Cell Cloning, 8(Suppl 1), pp.35~44 (1990)
- Crotti C, "Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis", Expert Opin Investig Drugs, 28, pp.573~581 (2019)
- Lang FM, "GM-CSF-based treatments in COVID-19:reconciling opposing therapeutic approaches", Nat Rev Immunol, 20, pp.507~514 (2020)
- Ramani T, "Cytokines: the good, the bad, and the deadly", Int J Toxicol, 34, pp.355~365 (2015)
- Di Franco M, "Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis", Core Evid, 9 (2014)
- Siddiqi HK, "COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal", J Heart Lung Transplant, 39, pp.405~407 (2020)
- Costela-Ruiz VJ, "SARS-CoV-2infection: The role of cytokines in COVID-19 disease", Cytokine Growth Factor Rev, 54, pp.62~75 (2020)
- Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
- Zhou Y, "Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients", Natl Sci Rev (2020)
- Lisi L, "Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2", Biochem Pharmacol, 180, pp.114169~ (2020)
- "Mavrilimumab in severe COVID-19 pneumonia and hyper-inflammation (COMBAT-19)"[URL]
- Cheng LL, "Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial", JAMA Intern Med, 181, pp.71~78 (2021)
- Cavalli G, "Interleukin-1 blockade with highdose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study", Lancet Rheumatol, 2, pp.e325~e331 (2020)
- De Luca G, "GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study", Lancet Rheumatol, 2, pp.e465~e473 (2020)
- "Mavrilimumab to reduce progression of acute respiratory failure in COVID-19 pneumonia and systemic hyper-inflmation. NCT04492514"[URL]
- "Study of Mavrilimumab (KPL-301) in participants hopistalized with severe corona virus disease 2019 (COVID-19) pneumonia and hyper-inflammation"[URL]
- "Mavrilimumab to reduce progression of acute respiratory failure in COVID-19 pneumonia and systemic hyper-inflammation. NCT04463004"[URL]
- Takeuchi T, "Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study", Mod Rheumatol, 2, pp.21~30 (2015)
- Burmester GR, "Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis", Arthritis Rheumatol, 70, pp.679~678 (2018)
- Weinblatt ME, "A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis", Arthritis Rheumatol, 70, pp.49~59 (2018)